Schedule 13G ownership disclosure
CNS PHARMACEUTICALS INC
Common Stock · CUSIP: 18978H508
Event date: 2025-10-29
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Stonepine Capital Management, LLC
Shares: 32,220.00 · Class: 5.6%
- Stonepine Capital, L.P.
Shares: 32,220.00 · Class: 5.6%
- Stonepine GP, LLC
Shares: 32,220.00 · Class: 5.6%
- Jon M. Plexico
Shares: 32,220.00 · Class: 5.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000935836-25-000648
- Form type
- SCHEDULE 13G
- Filer
- CNS Pharmaceuticals, Inc.
- CIK
- CIK 1729427
- Filed
- Nov 04, 2025
- Reporting period
- Oct 29, 2025
- Description
- Schedule 13G beneficial ownership